ARMISTICE CAPITAL, LLC
Q1 2023 13F-HR Holdings
Net value change ($000)
+1,212,604
(21.2%)
New positions
83
Sold out positions
50
Turnover %
16.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| UNH | 69,530 | 327.9% |
| CL | 63,134 | 793.3% |
| XRAY | 61,998 | 232.9% |
| JNJ | 60,373 | 569.6% |
| NBIX | 53,646 | 49.9% |
| Shockwave Medical, Inc. | 44,816 | 419.2% |
| DICE Therapeutics, Inc. | 39,422 | NEW |
| VRTX | 26,576 | 62.2% |
| TVTX | 25,915 | 19.2% |
| AUPH | 24,125 | 111.7% |
Top Reduces (Value $000, Stocks/ETFs)
| PCRX | -73,050 | -100.0% |
| REGN | -36,637 | -46.2% |
| FRPT | -34,149 | -30.3% |
| CVS | -32,766 | -73.9% |
| BUD | -29,900 | -100.0% |
| PARAV | -26,536 | -36.6% |
| CLX | -24,277 | -100.0% |
| Deciphera Pharmaceuticals, Inc. | -21,424 | -25.3% |
| Mirati Therapeutics, Inc. | -20,772 | -13.1% |
| KYNB | -18,759 | -30.3% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
2,644,351
(38.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|